This is a single arm, open-label, multicenter phase II clinical study to evaluate the safety and efficacy of 9MW2821 combined with Toripalimab in perioperative patients with urothelial cancer.
Sign the informed consent form approved by IEC.
Male or female subjects aged ≥18 years old.
ECOG status: 0 or 1.
Histologically confirmed urothelial cancer.
Prior systemic anti-tumor therapy for urothelial cancer.
Previously treated with PD-1/PD-L1 inhibitors or antibody-drug conjugates (ADCs).
History of another malignancy within 3 years.
History of autoimmune disease requiring systemic treatment within 2 years.